drugset / Trial / NCT07303881
Golidocitinib for Refractory Immune-related Hematologic Toxicities of Advanced Lung Cancer
Phase 2
Not yet recruiting
16 enrolled
The First Affiliated Hospital of Guangzhou Medical University
NaSingle-groupOpen-labelTreatment
Summary
This study is a single-arm clinical trial designed to evaluate the safety and efficacy of golidocitinib in patients with refractory, immune-related hematologic toxicity in advanced lung cancer.
Timeline
- Start
- 2026-02
- Primary completion
- 2027-06
- Completion
- 2028-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Golidocitinib | Small molecule | 75 mg | — |
| Subject | Golidocitinib | Small molecule | 150 mg | — |